Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label, Pilot Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Conditions
Interventions
Linperlisib
Locations
2
China
Zhoukou Central Hospital
Zhoukou, Henan, China
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
Start Date
February 10, 2023
Primary Completion Date
January 30, 2024
Completion Date
February 14, 2024
Last Updated
May 29, 2024
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions